Cargando…
To prescreen or not to prescreen for broadly neutralizing antibody sensitivity in HIV cure-related trials
The use of broadly neutralizing antibodies (bNAbs) as a cure-related research strategy for human immunodeficiency virus (HIV) has gained attention from the scientific community. bNAbs are specialized antibodies that target HIV-1 by binding to proteins on the surface of the virus, preventing the infe...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10491646/ https://www.ncbi.nlm.nih.gov/pubmed/37692548 http://dx.doi.org/10.1016/j.jve.2023.100339 |